In both trials, TransCon PTH was generally well tolerated, with no new safety signals identified. Most treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1 or 2) and no patients ...

Discover Sangamo Therapeutics’ Q3 2025 highlights: clinical progress in Fabry disease, FDA support for ST-920, extended cash runway, and partnership updates.

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated ...

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction ...

It also took the spot as the 12th leading cause of disability-adjusted life-years (DALYs), with an age-standardized DALY rate ...

ST-920 Clinical Data -- Positive mean annualized eGFR slope of nearly 2.0 observed at 52 weeks in all 32 patients; A mean annualized eGFR slope of 1.7 was observed in 19 patients with two years of ...

At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...

Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...

Ascendis Pharma (ASND) announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is ...

Scientific studies also reveal that Indian women are more likely to carry mutations such as EGFR, ALK, and ROS1, which are linked to non-small cell lung carcinoma (NSCLC)—a form of cancer increasingly ...

Cannabidiol (CBD) inhibits tumor growth in triple-negative breast cancer (TNBC), a highly aggressive form that lacks targeted ...